Opin vísindi

Fletta eftir höfundi "Santos, Maria Jose"

Fletta eftir höfundi "Santos, Maria Jose"

Röðun: Raða: Niðurstöður:

  • Icon
    Drug retention, inactive disease and response rates in 1860 patients with axial spondyloarthritis initiating secukinumab treatment: routine care data from 13 registries in the EuroSpA collaboration 
    Michelsen, Brigitte; Lindström, Ulf; Codreanu, Catalin; Ciurea, Adrian; Zavada, Jakub; Loft, Anne Gitte; Pombo-Suarez, Manuel; Onen, Fatos; Kvien, Tore K; Rotar, Ziga; Santos, Maria Jose; Iannone, Florenzo; Hokkanen, Anna-Mari; Gudbjornsson, Bjorn; Askling, Johan; Ionescu, Ruxandra; Nissen, Michael J; Pavelka, Karel; Sanchez-Piedra, Carlos; Akar, Servet; Sexton, Joseph; Tomsic, Matija; Santos, Helena; Sebastiani, Marco; Österlund, Jenny; Geirsson, Arni Jon; Macfarlane, Gary; van der Horst-Bruinsma, Irene; Georgiadis, Stylianos; Brahe, Cecilie Heegaard; Ørnbjerg, Lykke Midtbøll; Hetland, Merete Lund; Østergaard, Mikkel (BMJ, 2020-09-01)
    OBJECTIVES: To explore 6-month and 12-month secukinumab effectiveness in patients with axial spondyloarthritis (axSpA) overall, as well as across (1) number of previous biologic/targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs), (2) ...
  • Icon
    Effectiveness and treatment retention of TNF inhibitors when used as monotherapy versus comedication with csDMARDs in 15 332 patients with psoriatic arthritis. Data from the EuroSpA collaboration 
    Lindström, Ulf; Di Giuseppe, Daniela; Delcoigne, Bénédicte; Glintborg, Bente; Möller, Burkhard; Ciurea, Adrian; Pombo-Suarez, Manuel; Sanchez-Piedra, Carlos; Eklund, Kari; Relas, Heikki; Guðbjörnsson, Björn; Löve, Þorvarður Jón; Jones, Gareth T.; Codreanu, Catalin; Ionescu, Ruxandra; Nekvindova, Lucie; Závada, Jakub; Atas, Nuh; Yolbas, Servet; Fagerli, Karen Minde; Michelsen, Brigitte; Rotar, Ziga; Tomšič, Matija; Iannone, Florenzo; Santos, Maria Jose; Avila-Ribeiro, Pedro; Ørnbjerg, Lykke Midtbøll; Østergaard, Mikkel; Jacobsson, Lennart T.H.; Askling, Johan; Nissen, Michael J. (2021-06-03)
    Background Comedication with conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) during treatment with tumour necrosis factor inhibitors (TNFi) is extensively used in psoriatic arthritis (PsA), although the additive benefit remains ...
  • Icon
    Sex differences in the effectiveness of first-line tumour necrosis factor inhibitors in axial spondyloarthritis : Results from the EuroSpA Research Collaboration Network 
    Hellamand, Pasoon; Van De Sande, Marleen; Ørnbjerg, Lykke Midtbøll; Klausch, Thomas; Nurmohamed, Michael T.; Van Vollenhoven, Ronald F.; Nordström, Dan; Hokkanen, Anna Mari; Santos, Maria Jose; Vieira-Sousa, Elsa; Loft, Anne G.; Glintborg, Bente; Hetland, Merete Lund; Lindström, Ulf; Wallman, Johan K.; Michelsen, Brigitte; Klami Kristianslund, Eirik; Ciurea, Adrian; Nissen, Michael S.; Codreanu, Catalin; Mogosan, Corina; Macfarlane, Gary J.; Rotariu, Ovidiu; Rotar, Ziga; Tomšič, Matija; Castrejon, Isabel; Otero-Varela, Lucia; Guðbjörnsson, Björn; Geirsson, Árni Jón; Vencovský, Ji; Pavelka, Karel; Gulle, Semih; Zengin, Berrin; Iannone, Florenzo; Foti, Rosario; Ostergaard, Mikkel; Van Der Horst-Bruinsma, Irene (2023-12-12)
    Objective Evidence indicates reduced treatment effectiveness of TNFi in women with axial spondyloarthritis (axSpA) compared with men. We aimed to investigate sex differences in treatment response and retention rates over 24 months of follow-up in axSpA ...